The Phase 1a/b trial of ADRX-0405 is taking place at trial sites across the U.S., with first readouts expected in Q4 2025.

Monoclonal Antibodies IndustryThe global monoclonal antibodies (mAbs) industry, valued at USD 186 billion in 2021, is ...

According to latest analysis by Report Ocean, the global antibody drugs market is poised to grow by USD 91 billion during 2022-2028, progressing at a CAGR of 9.7% during the forecast period. Request ...

CLN-619 is under clinical development by Cullinan Therapeutics and currently in Phase I for Refractory Multiple Myeloma.

GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical stage biotechnology company focused on the development of ...

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive ...

This study is an open-label, dose-escalation/expansion Phase I clinical trial (NCT05920876), aiming to assess the safety of ...

In 2024, the field of myasthenia gravis (MG) saw many developments from clinical trials of new treatments, including ...

Casumo UK Eureka Biopharma announces preclinical results of its humanized antibody nasal spray to prevent COVID-19 infection AstraZeneca's dapagliflozin appro ...

INR:2228. harsh kumar kabaddi player Transcenta's humanized monoclonal antibody new drug TST001 is approved for clinical trials 『Pharmaceutical Headl ...

ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, announced today that the ...